3SOF

Ah good, pleased to hear I didn't trickle down this week by my lonesome. I too see that support just below $2.00 and will hold unless there's a significant move below that. I see good things in the near future 

MORE GOOD NEWS !!!!!!!

Press Release Source: Nutrition 21, Inc.


Nutrition 21 Receives Commitment from WellMed to Purchase Diachrome(R) for Patients with Diabetes
Tuesday April 18, 1:22 pm ET 
Diachrome incorporated into clinical guidelines for type 2 diabetes patients


PURCHASE, N.Y. & SAN ANTONIO--(BUSINESS WIRE)--April 18, 2006--Nutrition 21, Inc. (NXXI: NASDAQ) and WellMed Medical Management, Inc. today announced an agreement for a five-year program that will provide Diachrome® to people with type 2 diabetes who participate in WellMed's diabetes disease management program in San Antonio, Texas.
ADVERTISEMENT


WellMed is a physician-owned practice management company which owns ten clinics and provides management services to 18 additional clinics in the San Antonio area. WellMed will purchase Diachrome directly from Nutrition 21 and provide the product to their participants as a daily nutritional support regimen designed specifically for people with diabetes.

"The WellMed commitment results from our strategy of working directly with healthcare provider groups and disease management organizations to incorporate Diachrome into their treatment protocols," said Paul Intlekofer, COO of Nutrition 21. "WellMed appreciated Diachrome's unique value proposition in addressing a healthcare crisis in the United States. Having participated as a study center in our recently completed 447 subject study conducted with XLHealth, a disease management firm, WellMed's first hand experience with Diachrome led them to make a decision to not only recommend the product, but to buy it directly and provide it to their patients."

"Their commitment further heightens awareness of the safety and efficacy of Diachrome as an adjunct therapy for people with diabetes as we begin with our plan to roll-out Diachrome nationally in major drug chains and also continue to work with other managed care organizations," added Intlekofer.

Diachrome is a non-prescription, nutrient-based insulin sensitizer for adults who have type 2 diabetes that has shown a positive dual effect on blood sugar as well as lipid metabolism in clinical studies and practice. It is a patented composition with United States and international patent protection through 2017.

"We are excited about the opportunity to include Diachrome in our treatment regimen for people with diabetes," said George M. Rapier, III, M.D, CEO for WellMed. "We have seen compelling clinical evidence on Diachrome's safety and efficacy. Including this affordable complementary therapy into our current program will offer our diabetes participants another means of controlling their diabetes while substantially lessening the economic burden of the disease."

As part of the agreement, WellMed has included Diachrome in its clinical guidelines for providing care to patients with diabetes. Diachrome will be delivered initially to 1,500 WellMed patients participating in the WellMed diabetes disease management program. This number is expected to grow as more patients with diabetes are identified and moved into the disease management program and as WellMed's service locations expand. Diachrome is currently available at CVS/pharmacy in the Home Diagnostic/Diabetes Care section.

According to the American Diabetes Association, there are 18.2 million people in the United States, or 6.3 percent of the population, who have diabetes. The economic impact of diabetes was estimated at $132 billion in 2002, including direct medical expenditures and the costs of lost productivity. From 1997 to 2002, the per capita annual cost of diabetes rose 30 percent.

Was just about to post  Good news indeed! 

Nice to see some positive movement off this news from NXXI - am still holding, and have been underwater on this one of late.  However, both the 20ema and the steep ascending trendline on the linear chart seem to be providing support. 

Was getting held down at 2.42 yesterday though, and I wasn't too keen on the afternoon's profit taking, but looking at the 15 min chart, it looks very much like a bull flag, no?  Would like to see 2.42 get taken out today, and for NXXI to push back up to test the 2.60 level.

There does seem to be a lot of selling whenever it makes a sudden push upwards, but lets see what today brings, and whether NXXI still has the strength to break through the sellers.

NXXI has been forming a pennant following its recent move.  News out yesterday about their new CEO confirmed several new customers (including Walmart) and was taken very well by the market - leading to a surge in volume and price yesterday afternoon.  NXXI looks primed to breakout from this p0ennant and head up towards 3.00+.  Radar it.

http://biz.yahoo.com/bw/060426/20060426005971.html?.v=1

Bring it on!   

I'm still holding this stock long after the 4th edition contest is over!

Leaira

Nice one Leaira,

Have to admit that I sold out again on the last little run up as I wasn't happy with my entry and took the chance to get out near break-even.  Unfortunately, as always seems to happen, I put my money somewhwere else and tied it up while NXXI retraced.  So now if I want in I have to chase it.  Am looking for 2 things tomorrow.  Either it breaks above 2.64, the recent high, on solid volume in the morning, in which case I may try to get back in, or I'm looking for a bit of resistance at this level, in which case I would buy a retrace to 2.20-2.25, which is the base of a potentially new ascending triangle.  Not quite sure yet whethe we have a pennant breakout or a pattern morph, but the last 2 days volume look good, and potentially ready to break out to new highs.  Hopefully the intraday tomorrow will tell the story.

Am sure you are sitting pretty, but its a bit more tricky when your buy is right at the upper end of the consolidation range.  Maybe I didn't quite have the patience/nerve on this one after the recent runup.

With you, Leaira!  Still holding what I picked up in the 1.80s. Thanks again for the pick!

Well, I finally sold this stock after 2 months!  I ended up with a 43% profit by selling at 2.30, the 20-EMA.  Everything is starting to look very weak right now.  There are better plays out there.

Leaira

Applaud Leaira
A great play. Will be watching for you're picks

Snuck out two days ago myself, at 2.31. Gain of 22.8%. Thanks for the pick Leaira!

This ones in Play, again................$3.30 TARGET........

Jumped in at $2.05


Dutton Associates Announces Investment Opinion: Nutrition 21 Strong Buy Rating Maintained In Update Coverage By Dutton Associates
Wednesday May 17, 10:34 am ET


EL DORADO HILLS, Calif.--(BUSINESS WIRE)--May 17, 2006--Dutton Associates continues its coverage of Nutrition 21 (Nasdaq:NXXI - News), maintaining its rating at Strong Buy and raising its target price to $3.30. The 10-page report by Dutton senior analyst William R. Prather, R.Ph., M.D. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
ADVERTISEMENT
 

We believe Nutrition 21 is evolving from an ingredients supplier to a consumer health products company and has been successful in aggressively pursuing their commercialization efforts for Chromax, the first branded product line of chromium picolinate, and Diachrome. Recent announcements of N21's relationships with mass retailers and drug store chains combined with our review of their first formal investor presentation at the recent investor conference solidifies our belief in the Company's product line and their marketing and sales strategy. We are increasing our revenue and earnings estimates, reiterating our Strong Buy rating, and raising our price target to $3.30.

Should be getting some attention,
been spending some $ for marketing and has deals with major retailers.
A 50.0% Fibonacci retracement would have been at $1.66 area,seems to
have picked up nice support at $1.80

Volume: 1,293,374
Avg Vol (3m): 1,960,150

Technicals
Close Above the 13-day EMA
Percentage Gainer

Last Price Quote is:
2.75%above 13-day EMA
10.92%above 50-day EMA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $86.61 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 09/26/2006
Last Analyst Rating: Market Perform

Entry into a Material Definitive Agreement, Financial Statements and Exhibits



ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On August 15, 2006, the Company entered into a merger agreement (the "Agreement") dated as of August 15, 2006 with Iceland Health, Inc., a New York corporation ("Iceland Health"), for the merger of Iceland Health into N21 Acquisition Corp., a newly formed New York corporation that is wholly owned by the Company. Iceland Health is a privately held company that is owned by Mark Stenberg and Arnold Blair (the "Stockholders") and is in the business of marketing and selling fish oil and omega-3 fatty acids that are manufactured by an Iceland company. It markets its products through direct response channels including TV infomercials, print, radio, direct mail and internet e-commerce.

The closing under the agreement is scheduled for September 15, 2006, but is subject to satisfactory due diligence and other terms and conditions.

At the closing, the Company will pay or deliver to the Stockholders 8,000,000 shares of the Company's common stock; $1,000,000 in cash; $2,500,000 in notes that will be due in three years with 5% interest and that will be secured with the "Iceland Health" trade name and trade mark; and up to $2,500,000 in earn out payments based on 3% of the amount by which Net Sales of Eligible Products (each as defined) in successive one-year periods after the Closing exceed $10,000,000. The Company will be required to issue to the Stockholders up to 1.5 million additional shares of the Company's common stock if the volume weighted average price of the Company's common stock during the 30 trading days immediately preceding the first anniversary of the Closing is less than $2 per share.

After the closing, the Company will pay to the Stockholders the amount if any by which Working Capital (as defined) at the closing is more than $100,000, and the Stockholders will pay to the Company the amount if any by which working capital at the closing is less than $100,000.

The shares issued and issuable to the Stockholders at the closing will initially be restricted, but the Company will be required to file a registration statement for these shares within 90 days after the closing. Notwithstanding registration, the shares (except for a total of up to 920,000 shares to be transferred by the Stockholders to other persons) will be restricted so that no shares can be sold during the first year after the closing, one-third can be sold during the second year after the closing, and two thirds can be sold during the third year after the closing. The restrictions lapse on the third anniversary of the closing. Restrictions also lapse earlier upon sale of the Company or of all or substantially all of its assets or the purchase by any person or entity of 35% or more of the Company's then outstanding common stock.

Each Stockholder will at the closing enter into a three-year employment agreement with the Company that provides for a base salary of $225,000 per year. For each full fiscal year during a Stockholder's employment in which the Company has positive EBITDA, the Company will pay to him a bonus equal to 0.25% (but not more than $50,000) of the Company's direct response sales in excess of $30 million during such fiscal year, plus 2.5% (but not more than $100,000) of any direct response operating profits in excess of $3 million during such fiscal year. The employment agreement also provides that each Stockholder is to be granted options during the period ending December 31, 2007 based on the number of options granted to executives similarly situated, and that he will be eligible for additional options during the balance of his employment term. If the Company terminates the employment of a Stockholder other than For Cause (as defined), the Company will be required to pay to the Stockholder his base salary for 12 months or to the end of the term, whichever is less. The restrictions on shares issued and issuable to a Stockholder also lapse if there is a Final Determination (as defined) that the Stockholder's employment was terminated by the Company other than For Cause (as defined) or that the Stockholder terminated his employment with the Company for Good Reason (as defined).

Still keeping watch on NXXI...  looking to see a break of key 1.80 resistance.  This one has a habit of running fast and hard.  If it breaks 1.80 it could be at 2.20 in the blink of an eye